Africa saw a notable jump in mpox cases last week, with a continuing rise in novel clade 1b detections and shifts in ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA Pediatrics. Heidi L. Moline, MD, MPH, ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...